COVID - search results

A molecular "decoy," a version of ACE2, protected 100 percent of study mice from COVID-19 when they were infected with an otherwise lethal dose of SARS-CoV-2.

Using next generation sequencing, biomarkers of COVID-linked multisystem inflammatory syndrome (MIS-C) have been found. The biomarkers are linked to organ damage.

Japanese research suggests that the digestion of fucose sugar by gut bacteria could impact the immune response to COVID-19 mRNA vaccines.

Infection with SARS-CoV-19 increases the risk of developing incident diabetes after recovering from the infection. Naveed Janjua from the British Columbia Centre for Disease Control, and colleagues report that 3–5% of incident diabetes cases in the study could be attributed to COVID-19.

A team of researchers at the University of Helsinki, Finland, report they have developed a molecule that can be administered nasally to prevent the development of COVID-19 symptoms by all known variants of the SARS-CoV-2 virus.

Overall risks of venous thromboembolism after COVID-19 are low in patients with less severe infections who do not require hospitalization.

Researchers have identified a potential new class of oral, antiviral drugs that could combat emerging coronaviruses and drug-resistant variants.

Scientists use the nasal monoclonal antibody “Foralumab” to successfully decrease inflammation in patients with COVID-19.

A test using a puff of breath might be used to discern even variants of COVID-19 from non-COVID respiratory diseases.

The presence of autoantibodies against inflammatory chemokines after COVID-19 could protect against the development of long COVID.